A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 71
- Registration Number
- NCT04255862
- Locations
- 🇩🇪
Up0068 001, Berlin, Germany
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 505
- Registration Number
- NCT04242446
- Locations
- 🇺🇸
Hs0003 50270, Seattle, Washington, United States
🇺🇸Hs0003 50149, San Antonio, Texas, United States
🇺🇸Hs0003 50175, Phoenix, Arizona, United States
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 509
- Registration Number
- NCT04242498
- Locations
- 🇺🇸
Hs0004 50184, Pembroke Pines, Florida, United States
🇺🇸Hs0004 50223, Savannah, Georgia, United States
🇺🇸Hs0004 50199, Miami, Florida, United States
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 200
- Registration Number
- NCT04225871
- Locations
- 🇺🇸
Mg0011 41, Mobile, Alabama, United States
🇺🇸Mg0011 116, Phoenix, Arizona, United States
🇺🇸Mg0011 31, Irvine, California, United States
A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- Other: Placebo
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 30
- Registration Number
- NCT04224688
- Locations
- 🇷🇺
Tp0006 20053, Saint Petersburg, Russian Federation
🇺🇦Tp0006 20061, Cherkasy, Ukraine
🇺🇦Tp0006 20064, Kyiv, Ukraine
A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- Other: Placebo
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 33
- Registration Number
- NCT04200456
- Locations
- 🇺🇦
Tp0003 20062, Ivano-frankivsk, Ukraine
🇺🇦Tp0003 20100, Zaporizhzhia, Ukraine
🇲🇩Tp0003 20051, Chisinau, Moldova, Republic of
A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 25
- Registration Number
- NCT04185415
- Locations
- 🇬🇧
Psp003 40166, London, United Kingdom
🇩🇪Psp003 40278, Essen, Germany
🇪🇸Psp003 40267, Barcelona, Spain
A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
- Conditions
- Psoriatic ArthritisAxial SpondyloarthritisPlaque PsoriasisRheumatoid ArthritisCrohn's Disease
- Interventions
- Drug: Pharmacokinetics of certolizumab pegol
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 22
- Registration Number
- NCT04163016
- Locations
- 🇨🇭
Up0085 300, Bern, Switzerland
🇫🇷Up0085 500, Paris, France
🇺🇸Up0085 104, Minneapolis, Minnesota, United States
A Study to Test the Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants
- Conditions
- Healthy Female Participants
- Interventions
- Drug: Microgynon 30®
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 14
- Registration Number
- NCT04131517
- Locations
- 🇬🇧
Up0035 001, London, United Kingdom
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 71
- Registration Number
- NCT04124965
- Locations
- 🇺🇸
Mg0004 50088, Washington, District of Columbia, United States
🇨🇦Mg0004 50070, Québec, Canada
🇺🇸Mg0004 50096, Philadelphia, Pennsylvania, United States